Innovation required in risk assessment of nanoparticles The currently existing models and techniques provide insufficient certainties in the assessment of the harmfulness of nanoparticles and nanomaterials to people and the environment.
RIVM participates in large EU project to head up global fight against infectious diseases COMPARE, a large EU project intends to speed up the detection of, and response to disease outbreaks among humans and animals worldwide, through the use of new genome technology.
No new MERS patients in the Netherlands Almost two months ago, two Dutch people were diagnosed with the MERS coronavirus.
International study finds MERS coronavirus in raw dromedary camel milk Milk from dromedary camels infected with the MERS coronavirus may contain the virus, and consuming this raw milk may thus pose a risk to public health.
Clinical condition Dutch MERS patients improving The two patients who were diagnosed last week with the MERS coronavirus are now on the mend.
The MERS-coronavirus in the Netherlands As of 13 May 2014, RIVM and Erasmus MC have diagnosed the MERS coronavirus in two Dutch people. The patients are related and were infected during a joint journey to Saudi Arabia.
RIVM film about nanomaterials RIVM contributes to the safe use of nanomaterials through research, alerts and policy consultations, and this work is demonstrated in a short informative film.
RIVM to research safe design for new nanoparticles RIVM will be working alongside a consortium of 23 international partners on a safe design for ‘new’ nanoparticles.
Nanotechnology in the fight against cancer Nanotechnology offers improved options for the diagnosis and treatment of cancer.
Is screening for sexually transmitted infections as part of HIV care cost-effective in the Netherlands? Routine screening for anorectal chlamydia among HIV-positive men who have sex with men (MSM) could avert further spread of chlamydia and HIV in the total MSM population.